Shares of Cellular Biomedicine Group Inc (NASDAQ:CBMG) have been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a one year consensus price target of $38.00 for the company and are expecting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cellular Biomedicine Group an industry rank of 85 out of 255 based on the ratings given to related companies.
CBMG has been the subject of several research reports. Zacks Investment Research upgraded shares of Cellular Biomedicine Group from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Friday, October 5th. B. Riley lifted their target price on shares of Cellular Biomedicine Group from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 3rd. Finally, BidaskClub downgraded shares of Cellular Biomedicine Group from a “hold” rating to a “sell” rating in a report on Friday.
CBMG traded up $0.06 during trading on Tuesday, reaching $12.38. The company’s stock had a trading volume of 72,668 shares, compared to its average volume of 93,857. Cellular Biomedicine Group has a 1 year low of $9.45 and a 1 year high of $25.00.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.01). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 47.52% and a negative net margin of 10,133.88%. Sell-side analysts forecast that Cellular Biomedicine Group will post -1.74 EPS for the current fiscal year.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.